Teprotumumab is associated with a greater reduction in proptosis than placebo at 24 weeks among adults with chronic thyroid eye disease and a low clinical activity score, according to topline results.
As Healio previously reported, data from phase 2 and phase 3 trials revealed teprotumumab (Tepezza, Horizon Therapeutics) met its primary endpoint of reducing proptosis among adults recently diagnosed with thyroid eye disease and those with higher clinical activity scores. The data led to teprotumumab becoming the first FDA-approved drug for the treatment of thyroid eye disease in January 2020.